| |
CAR-T therapies have transformed treatment for certain hematological malignancies, but their use is limited. Ongoing research seeks to improve safety, efficacy, and lower costs, expanding their application. To learn more, download our white paper.
|
|
Today’s Big NewsSep 16, 2024 |
|
As stated in guidance, it's important to understand the selectivity and potency of inhibitors, so BioIVT shared results of CYP inactivation for a variety of commonly used inhibitors... Read More >>
|
|
| By Nick Paul Taylor AstraZeneca has shared an early look at the performance of its in-house antibody-drug conjugate technology, publishing phase 1 data on candidates that could compete with molecules from AbbVie and Pfizer. |
|
|
|
By James Waldron Novo Nordisk isn’t letting up on the RNA deals, this time penning a $530 million biobucks deal to work with Korro Bio on two cardiometabolic-related targets. |
By Nick Paul Taylor Cancer patients with wasting syndrome have gained weight after taking Pfizer’s anti-GDF-15 antibody in a midphase study, emboldening the Big Pharma to target a 2025 start date for its pivotal trial program. |
Sponsored by Avacare Clinical Research Network With intricate protocols and shifting regulatory demands, it’s more difficult than ever to find and keep participants, as well as gather reliable data. |
|
Create an optimal path to the clinic that best suits your molecule and critical milestones. We now offer a full suite of integrated drug substance/drug product DNA-to-IND programs to accelerate any molecule type to the clinic. Download our white papers to learn more about our tailored CMC strategies.
|
|
By Nick Paul Taylor Bristol Myers Squibb has jettisoned another cancer candidate in-licensed under its former CEO. Immatics is the latest partner to get a termination notice, leaving it in full control of a bispecific molecule that BMS picked up for $150 million upfront late in 2021. |
By Gabrielle Masson After announcing a phase 3 launch based on positive midstage results, iTeos and GSK are finally sharing the highlights from the phase 2 TIGIT trial, revealing a more than 30% difference in confirmed overall response rates between the investigational treatment versus monotherapy. |
By Gabrielle Masson Regeneron is back with long-term follow-up results for its LAG-3 inhibitor and PD-1 inhibitor combo in advanced melanoma, phase 1 findings that have prompted the company to launch four phase 3 programs with the intent to rival Bristol Myers Squibb's Opdualag. |
By James Waldron Lantheus may have been hoping that “statistically significant” phase 3 data for its radioligand therapy would make a splash at ESMO, but not everyone is impressed. |
By Nick Paul Taylor Boehringer Ingelheim has ended a decade of industrywide failures in idiopathic pulmonary fibrosis by reporting a phase 3 win for a potentially first-in-class candidate and outlining plans to seek approval. |
By James Waldron Jazz Pharmaceuticals has posted fresh phase 2 data on zanidatamab that show the HER2-targeted bispecific antibody kept 59% of people with metastatic gastroesophageal cancer alive for at least 30 months. |
By Darren Incorvaia Immune checkpoint inhibitors are the superheroes of cancer therapy. Drugs like Bristol Myers Squibb’s Opdivo and Merck’s Keytruda are among the most profitable in the world—Keytruda pulled in $25 billion last year, making it the bestselling drug of 2023. But every good superhero needs a sidekick. |
By Darren Incorvaia Another contender has emerged in the race to develop oral GLP-1 drugs for weight loss. Biolexis Therapeutics’ small molecule BLX-7006 reduced the weight of obese mice by 15% over a 28-day span. |
By Darren Incorvaia Four years after launching a remote-controlled robotic laboratory in San Diego, Eli Lilly is shipping the operation overseas. The Big Pharma is selling a majority of the Life Sciences Studio laboratory to Arctoris, a contract research organization with headquarters in Oxford, England and Boston. |
By Heather Landi Walgreens sees a long runway for its two-year-old clinical trials business as it doubles down on its core retail pharmacy operations. Ramita Tandon, chief clinical trials officer, shared insights about Walgreens' strategy to ramp up its clinical research capabilities during TD Cowen’s recent 9th Annual FutureHealth Conference. |
By Angus Liu In 2021, the FDA blasted Merck for using premature data to pursue a Keytruda approval in early-stage triple-negative breast cancer. Now, the PD-1 inhibitor has gold-standard overall survival data to back its case. |
Fierce podcastsDon’t miss an episode |
| | In this week's episode of "The Top Line," we will dive into the annual Fierce 50 special report. |
|
|---|
|
|
| WhitepaperUnique Solutions for Drug Discovery and Development Sponsored by: Cell Signaling Technology |
| WhitepaperWhen the fate of your company hangs in the balance, you need expert guidance to navigate the complexities of biotechnology development and to make informed decisions. Sponsored by: WCG |
| WhitepaperPower non-invasive, self-sampling solutions using the Colli-Pee™️ first-void urine collection device. Learn more. Sponsored by: DNA Genotek |
| Whitepaper Facing roadblocks in drug development? Uncover how phase-appropriate technology transfers can help you navigate challenges and speed up your journey to market. Sponsored by: Veranova |
| WhitepaperWe interviewed dozens of biopharma leaders on the critical success factors for building a Best Practice commercial organization. This report shares what we learned. Sponsored by: Blue Matter Consulting |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
